This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study by Dr Strawford and colleagues¹ contributes important data regarding anabolic steroid treatment of human immunodeficiency virus (HIV)–associated wasting. In an Editorial,² Dr Dobs noted that this study was "limited by absence of an exercise arm alone."

We recently completed a pilot study³ on oxandrolone and progressive resistance exercise in a similar group of HIV-positive subjects with a greater than 5% weight loss. All study participants (12 men, 1 woman) received 10 mg of oxandrolone twice a day and were randomized to progressive resistance exercise (n=7) or no progressive resistance exercise (n=6) groups. Study participants had an average of 9.4% and 11.0% muscle wasting and had average logarithmic viral loads of 3.4 and 3.5, in the progressive resistance exercise and control groups, respectively. Group parameters did not differ significantly. Stable physiologic testosterone supplementation in study participants was permitted. Applicants with abnormal liver function test results, pregnancy, . . . [Full Text of this Article]

RELATED ARTICLE

Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial
Alison Strawford, Theresa Barbieri, Marta Van Loan, Elizabeth Parks, Don Catlin, Norman Barton, Richard Neese, Mark Christiansen, Janet King, and Marc K. Hellerstein
JAMA. 1999;281(14):1282-1290.
ABSTRACT | FULL TEXT